Related references
Note: Only part of the references are listed.SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among US Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis
Evan J. Anderson et al.
AMERICAN JOURNAL OF PERINATOLOGY (2017)
Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study
Manuel Sanchez-Luna et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2017)
Examination of neurological prognostic markers in patients with respiratory syncytial virus-associated encephalopathy
Shinichiro Morichi et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2017)
Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
B. Resch et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis
M. Cetinkaya et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015)
Daniel Y. Wang et al.
EUROPEAN JOURNAL OF PEDIATRICS (2017)
Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
Bernhard Resch et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design
Emma Rey-Jurado et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience
Bavani Rajah et al.
JOURNAL OF PEDIATRICS (2017)
Respiratory syncytial virus-Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life
Giovanni A. Rossi et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2017)
In Reply: Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
Carlina J. Grindeland et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy An International, Prospective Cohort Study
Paolo Manzoni et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis
Jakob Metz et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
Christopher S. Ambrose
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
Asuncion Mejias et al.
VACCINE (2017)
Animal models of respiratory syncytial virus infection
Geraldine Taylor
VACCINE (2017)
Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: is there still room for debating?
Gianvincenzo Zuccotti et al.
ITALIAN JOURNAL OF PEDIATRICS (2017)
Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease
B. Resch et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)
Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review
Clare E. French et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2016)
Viral Bronchiolitis in Children
H. Cody Meissner
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
Carlina J. Grindeland et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease
Maria Serenella Pignotti et al.
PEDIATRIC PULMONOLOGY (2016)
Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab
Pascal M. Lavoie et al.
JAMA PEDIATRICS (2016)
Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases
Ah Young Kim et al.
KOREAN CIRCULATION JOURNAL (2016)
Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
Louis Bont et al.
INFECTIOUS DISEASES AND THERAPY (2016)
New options in the treatment of respiratory syncytial virus disease
Asuncion Mejias et al.
JOURNAL OF INFECTION (2015)
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial
Katherine L. O'Brien et al.
LANCET INFECTIOUS DISEASES (2015)
Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab
Parco Chan et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants
Ram Yogev et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Efficacy and Optimization of Palivizumab Injection Regimens Against Respiratory Syncytial Virus Infection
Alexander Gutfraind et al.
JAMA PEDIATRICS (2015)
Leukotriene inhibitors for bronchiolitis in infants and young children
Fang Liu et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals
Joanna Murray et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2014)
RSV-Still More Questions Than Answers
Louis Bont et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study
Hao Yi et al.
PEDIATRICS (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation
Gabriel J. Robbie et al.
INFECTIOUS DISEASES AND THERAPY (2014)
Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity
Doris Makari et al.
INFECTIOUS DISEASES AND THERAPY (2014)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union
Dianne van Beek et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Maarten O. Blanken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
Tea Andabaka et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention
P. Manzoni et al.
EARLY HUMAN DEVELOPMENT (2012)
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
B. Paes et al.
EUROPEAN JOURNAL OF PEDIATRICS (2012)
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria
Bernhard Resch et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006-2010
Jesse Papenburg et al.
EMERGING INFECTIOUS DISEASES (2012)
Are late preterm infants as susceptible to RSV infection as full term infants?
Bernhard Resch et al.
EARLY HUMAN DEVELOPMENT (2011)
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
D. Wang et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
Paul A. Checchia et al.
PEDIATRIC CRITICAL CARE MEDICINE (2011)
A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease
Timothy F. Feltes et al.
PEDIATRIC RESEARCH (2011)
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
Pilar Fernandez et al.
BMC PEDIATRICS (2010)
A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
Michael P. Frogel et al.
JOURNAL OF MANAGED CARE PHARMACY (2010)
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair et al.
LANCET (2010)
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Xavier Carbonell-Estrany et al.
PEDIATRICS (2010)
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life
Nele Sigurs et al.
THORAX (2010)
Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection
K. Thorburn
ARCHIVES OF DISEASE IN CHILDHOOD (2009)
Incidence of Apnea in Infants Hospitalized with Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
Shawn Ralston et al.
JOURNAL OF PEDIATRICS (2009)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes
Bernhard Resch et al.
PAEDIATRIC RESPIRATORY REVIEWS (2009)
SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)-SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN
Rosanna Lagos et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Policy Statement-Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
Joseph A. Bocchini et al.
PEDIATRICS (2009)
Crystal Structure of a Nucleocapsid-Like Nucleoprotein-RNA Complex of Respiratory Syncytial Virus
Rajiv G. Tawar et al.
SCIENCE (2009)
Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants
Bernhard Resch
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract
Herren Wu et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation
C Flamant et al.
EUROPEAN JOURNAL OF PEDIATRICS (2005)
Deaths among children less than two years of age receiving palivizumab:: an analysis of comorbidities
AK Mohan et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Compliance with prophylaxis for respiratory syncytial virus infection in a home setting
SG Golombek et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants
JP DeVincenzo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection
X Sáez-Llorens et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
TF Feltes et al.
JOURNAL OF PEDIATRICS (2003)
Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection
JR Groothuis
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2003)
Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody
JP DeVincenzo et al.
JOURNAL OF PEDIATRICS (2003)
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry
C Parnes et al.
PEDIATRIC PULMONOLOGY (2003)
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection
T Lacaze-Masmonteil et al.
DRUG SAFETY (2003)
Immunological mechanisms of severe respiratory syncytial virus bronchiolitis
L Bout et al.
INTENSIVE CARE MEDICINE (2002)
Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants
J Young
RESPIRATORY MEDICINE (2002)
Respiratory syncytial virus prophylaxis - the story so far
EAF Simoes et al.
RESPIRATORY MEDICINE (2002)
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial
JR Groothius
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2001)
A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways
G Piedimonte et al.
PEDIATRIC RESEARCH (2000)
Share Paper
